drugset / Trial / NCT01340430
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2 (HER2) positive non operable breast cancer
Timeline
- Start
- 2011-03
- Primary completion
- 2015-12
- Completion
- 2022-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Epirubicin | Small molecule | 90 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Background | fluorouracil | Small molecule | 600 mg/m2 | — |